Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriáza - imunosupresiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastická činidla - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastická činidla - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

vbi vaccines b.v. - povrchový antigen hepatitidy b - Žloutenka typu b - vakcíny - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leukemie, myelogenní, chronická, bcr-abl pozitivní - antineoplastická činidla - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

octapharma (ip) sprl, brusel array - 4729 antitrombin iii - prášek a rozpouštědlo pro infuzní roztok - 50iu/ml - antitrombin iii

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

octapharma (ip) sprl, brusel array - 1675 lidskÝ fibrinogen - prášek a rozpouštědlo pro injekční/infuzní roztok - 1g - lidskÝ fibrinogen

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto array - 16298 imatinib-mesilÁt - potahovaná tableta - 100mg - imatinib

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto slovinsko - 16298 imatinib-mesilÁt - dispergovatelná tableta - 100mg - imatinib

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto array - 16298 imatinib-mesilÁt - potahovaná tableta - 400mg - imatinib